Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

venetoclax 4ibrutinib 4obinutuzumab 3fludarabine phosphate 3fludarabine 3Mesna 3Cyclophosphamide 3Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Melphalan 2Busulfan 2zanubrutinib 1ricolinostat 1idelalisib 1acalabrutinib 1Bone Marrow Transplantation 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, B-Cell × idelalisib × Clear all
NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡